---
document_datetime: 2025-12-29 14:33:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/quintanrix.html
document_name: quintanrix.html
version: success
processing_time: 0.117782
conversion_datetime: 2025-12-30 12:07:23.142388
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Quintanrix

[RSS](/en/individual-human-medicine.xml/65582)

##### Withdrawn

This medicine's authorisation has been withdrawn

diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed) Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 1 August 2008, the marketing authorisation holder (MAH) responsible for Quintanrix, GlaxoSmithKline Biologicals, notified the European Commission of its decision to voluntarily withdraw the marketing authorisation for Quintanrix for commercial reasons. The MAH confirmed that this decision is not related to any safety concerns with Quintanrix.

Quintanrix was never marketed in the European Union. Quintanrix (diphtheria, tetanus, pertussis [whole cell], hepatitis B [rDNA] and Haemophilus type b conjugate vaccine [adsorbed]) was indicated for primary immunisation of infants during the first year of life against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and invasive diseases caused by Haemophilus influenzae type b ('Hib', a bacterium that causes meningitis), and for booster immunisation of young children during the second year of life. Alternative vaccines are available throughout the European Union. These contain the same active substances as Quintanrix (diphtheria toxoid, tetanus toxoid, inactivated Bordetella pertussis [a bacterium that causes whooping cough], recombinant hepatitis B surface antigen [r-HBsAg, parts of the hepatitis B virus] and Hib polysaccharides [sugars from the bacterium Hib]).

On 28 August 2008, the European Commission issued a decision to withdraw the marketing authorisation for Quintanrix. Pursuant to this decision, the European public assessment report (EPAR) for Quintanrix is updated to reflect that the marketing authorisation is no longer valid.

Quintanrix : EPAR - Summary for the public

English (EN) (269.15 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/overview/quintanrix-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-425)

български (BG) (707.73 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/bg/documents/overview/quintanrix-epar-summary-public_bg.pdf)

español (ES) (272.44 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/es/documents/overview/quintanrix-epar-summary-public_es.pdf)

čeština (CS) (663.01 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/cs/documents/overview/quintanrix-epar-summary-public_cs.pdf)

dansk (DA) (491.22 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/da/documents/overview/quintanrix-epar-summary-public_da.pdf)

Deutsch (DE) (271.04 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/de/documents/overview/quintanrix-epar-summary-public_de.pdf)

eesti keel (ET) (267.37 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/et/documents/overview/quintanrix-epar-summary-public_et.pdf)

ελληνικά (EL) (708.22 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/el/documents/overview/quintanrix-epar-summary-public_el.pdf)

français (FR) (271.64 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fr/documents/overview/quintanrix-epar-summary-public_fr.pdf)

italiano (IT) (271.02 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/it/documents/overview/quintanrix-epar-summary-public_it.pdf)

latviešu valoda (LV) (423.62 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lv/documents/overview/quintanrix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (389.43 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lt/documents/overview/quintanrix-epar-summary-public_lt.pdf)

magyar (HU) (407.14 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/hu/documents/overview/quintanrix-epar-summary-public_hu.pdf)

Malti (MT) (415.74 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/mt/documents/overview/quintanrix-epar-summary-public_mt.pdf)

Nederlands (NL) (271.79 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/nl/documents/overview/quintanrix-epar-summary-public_nl.pdf)

polski (PL) (425.91 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pl/documents/overview/quintanrix-epar-summary-public_pl.pdf)

português (PT) (271.95 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pt/documents/overview/quintanrix-epar-summary-public_pt.pdf)

română (RO) (384.57 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/ro/documents/overview/quintanrix-epar-summary-public_ro.pdf)

slovenčina (SK) (411.96 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sk/documents/overview/quintanrix-epar-summary-public_sk.pdf)

slovenščina (SL) (401.92 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sl/documents/overview/quintanrix-epar-summary-public_sl.pdf)

Suomi (FI) (270.91 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fi/documents/overview/quintanrix-epar-summary-public_fi.pdf)

svenska (SV) (269.96 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sv/documents/overview/quintanrix-epar-summary-public_sv.pdf)

## Product information

Quintanrix : EPAR - Product Information

English (EN) (567.88 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/product-information/quintanrix-epar-product-information_en.pdf)

[Other languages (21)](#file-language-dropdown-980)

български (BG) (1.31 MB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/bg/documents/product-information/quintanrix-epar-product-information_bg.pdf)

español (ES) (577.53 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/es/documents/product-information/quintanrix-epar-product-information_es.pdf)

čeština (CS) (1.04 MB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/cs/documents/product-information/quintanrix-epar-product-information_cs.pdf)

dansk (DA) (892.46 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/da/documents/product-information/quintanrix-epar-product-information_da.pdf)

Deutsch (DE) (590.38 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/de/documents/product-information/quintanrix-epar-product-information_de.pdf)

eesti keel (ET) (532.26 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/et/documents/product-information/quintanrix-epar-product-information_et.pdf)

ελληνικά (EL) (856.83 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/el/documents/product-information/quintanrix-epar-product-information_el.pdf)

français (FR) (558.76 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fr/documents/product-information/quintanrix-epar-product-information_fr.pdf)

italiano (IT) (601.36 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/it/documents/product-information/quintanrix-epar-product-information_it.pdf)

latviešu valoda (LV) (752.51 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lv/documents/product-information/quintanrix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (661.88 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lt/documents/product-information/quintanrix-epar-product-information_lt.pdf)

magyar (HU) (650.11 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/hu/documents/product-information/quintanrix-epar-product-information_hu.pdf)

Malti (MT) (688.81 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/mt/documents/product-information/quintanrix-epar-product-information_mt.pdf)

Nederlands (NL) (578.25 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/nl/documents/product-information/quintanrix-epar-product-information_nl.pdf)

polski (PL) (735.09 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pl/documents/product-information/quintanrix-epar-product-information_pl.pdf)

português (PT) (533.36 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pt/documents/product-information/quintanrix-epar-product-information_pt.pdf)

română (RO) (678.33 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/ro/documents/product-information/quintanrix-epar-product-information_ro.pdf)

slovenčina (SK) (665 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sk/documents/product-information/quintanrix-epar-product-information_sk.pdf)

slovenščina (SL) (608.89 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sl/documents/product-information/quintanrix-epar-product-information_sl.pdf)

Suomi (FI) (540.45 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fi/documents/product-information/quintanrix-epar-product-information_fi.pdf)

svenska (SV) (866.59 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sv/documents/product-information/quintanrix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0008 11/12/2007

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Quintanrix : EPAR - All Authorised presentations

English (EN) (506.88 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-149)

español (ES) (508.64 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/es/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (581.82 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/cs/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (507.79 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/da/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (514.33 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/de/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (508.85 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/et/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (603.3 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/el/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_el.pdf)

français (FR) (509.39 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fr/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (505.08 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/it/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (581.66 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lv/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (535.93 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/lt/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (563.91 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/hu/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (296.22 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/nl/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_nl.pdf)

polski (PL) (347.16 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pl/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_pl.pdf)

português (PT) (296.72 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/pt/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (344.71 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sk/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (337.81 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sl/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (505.24 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/fi/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (531.18 KB - PDF)

**First published:**

10/09/2008

**Last updated:**

10/09/2008

[View](/sv/documents/all-authorised-presentations/quintanrix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Quintanrix Active substance

- Diphtheria toxoid
- tetanus toxoid
- inactivated Bordetella pertussis
- hepatitis B surface antigen (rDNA)
- Haemophilus influenzae type b polysaccharide

International non-proprietary name (INN) or common name diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed) Therapeutic area (MeSH)

- Hepatitis B
- Tetanus
- Immunization
- Meningitis, Haemophilus
- Whooping Cough
- Diphtheria

Anatomical therapeutic chemical (ATC) code J07CA10

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Haemophilus influenzae type b and for booster immunisation of young children during the second year of life.

## Authorisation details

EMA product number EMEA/H/C/000556 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89 B-1330 Rixensart Belgium

Marketing authorisation issued 17/02/2005 Withdrawal of marketing authorisation 28/08/2008 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Quintanrix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (450.97 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/procedural-steps-after/quintanrix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Quintanrix : EPAR - Procedural steps taken before authorisation

English (EN) (511.91 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/procedural-steps/quintanrix-epar-procedural-steps-taken-authorisation_en.pdf)

Quintanrix : EPAR - Scientific Discussion

English (EN) (718.38 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/scientific-discussion/quintanrix-epar-scientific-discussion_en.pdf)

**This page was last updated on** 10/09/2008

## Share this page

[Back to top](#main-content)